Trial · NCT03126435
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | EndoTAG-1 and Gemcitabine | 226 | 95% Confidence Interval 183.0 to 278.0 | days | |
| Overall Survival | Gemcitabine Monotherapy | 209 | 95% Confidence Interval 158.0 to 248.0 | days | |
| Progression Free Survival (PFS) | EndoTAG-1 and Gemcitabine | 113 | 95% Confidence Interval 79.0 to 168.0 | days | |
| Progression Free Survival (PFS) | Gemcitabine Monotherapy | 110 | 95% Confidence Interval 60.0 to 115.0 | days | |
| Percentage of Subjects With Objective Response | EndoTAG-1 and Gemcitabine | 11 | Participants | ||
| Percentage of Subjects With Objective Response | Gemcitabine Monotherapy | 6 | Participants | ||
| Duration of Response | EndoTAG-1 and Gemcitabine | 5.8 | Standard Deviation 2.62 | Months | |
| Duration of Response | Gemcitabine Monotherapy | 9.1 | Standard Deviation 6.97 | Months | |
| Percentage of Subjects With Disease Control According to RECIST v.1.1 | EndoTAG-1 and Gemcitabine | 57 | Participants | ||
| Percentage of Subjects With Disease Control According to RECIST v.1.1 | Gemcitabine Monotherapy | 43 | Participants | ||
| Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate | EndoTAG-1 and Gemcitabine | 2 | Participants | ||
| Serum Carcinoma Antigen 19-9 (CA 19-9) Response Rate | Gemcitabine Monotherapy | 2 | Participants | ||
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score | EndoTAG-1 and Gemcitabine | Pancreatic pain | 1.0 | Standard Deviation 3.0 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score | Gemcitabine Monotherapy | Pancreatic pain | 1.7 | Standard Deviation 3.2 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score | EndoTAG-1 and Gemcitabine | Digestive | 0.6 | Standard Deviation 2.1 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score | Gemcitabine Monotherapy | Digestive | 0.9 | Standard Deviation 1.6 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score | EndoTAG-1 and Gemcitabine | Altered bowel habit | 0.5 | Standard Deviation 1.8 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score | Gemcitabine Monotherapy | Altered bowel habit | -0.1 | Standard Deviation 1.5 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score | EndoTAG-1 and Gemcitabine | Hepatic | 0.0 | Standard Deviation 0.9 | score on a scale |
| Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score | Gemcitabine Monotherapy | Hepatic | 0.0 | Standard Deviation 1.1 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03126435/results